Boston Scientific (NYSE:BSX – Free Report) had its price objective raised by Piper Sandler from $95.00 to $115.00 in a ...

Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices. Manufacturers of medical devices have been ...

Boston Scientific (NYSE:BSX – Get Free Report) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Wednesday. Several other research analysts also ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

But there’s a powerful fundamental story happening with Boston Scientific. Also, EPS is estimated to ramp higher this year by +13.8%. Now it makes sense why the stock has been powering to new ...

BSX shares have continued to outpace competitors like Abbott, Johnson & Johnson, and Medtronic, driven by strong performance across multiple business lines. Innovative atrial fibrillation devices ...

Expert Rev Gastroenterol Hepatol. 2012;6(1):105-114. When double-stent placement (duodenal and biliary) is considered, biliary stent placement can be performed either preceding or following ...

The Farapulse (left) and Watchman FLX Pro (right) systems. [Images courtesy of Boston Scientific] Boston Scientific (NYSE: BSX) + CEO Mike Mahoney expects more growth for the company in 2025.

Boston Scientific Corporation today announced it has entered into a definitive agreement to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy (IVL) advanced laser-based ...